Skip to content

Study · Systematic review · 2025

5 results

Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.

Misra S, Narayan RK, Kaur M

Journal of basic and clinical physiology and pharmacology21 Jul 2025Cited by 1 (Europe PMC)

PMID40728138 (opens in a new tab)DOI10.1515/jbcpp-2025-0113 (opens in a new tab)PepBankPUB-40728138
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with obesity, retatrutide 12 mg gave the largest body weight reductions, and weekly subcutaneous retatrutide caused significant weight loss compared with placebo (systematic review of three trials).

    In plain wordsIn adults with obesity, weekly retatrutide injections led to more weight loss than placebo, most at the 12 mg dose.

    Peptide
    Retatrutide
    Outcome
    DecreaseBody weight reduction
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    12 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The 12 mg dosage of retatrutide showed the most significant reductions in body weight, body mass index, and waist circumference.
    3 context sentences
    Summary · context
    Weekly subcutaneous injections of retatrutide in obese patients resulted in significant weight loss and metabolic improvements compared to a placebo.
    Summary · context
    Three articles were included in this systematic review, screening a total of 1,082 patients, with 691 randomly assigned to groups.
    Summary · context
    Retatrutide was administered to 510 participants, while 130 received a placebo.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with obesity, retatrutide 12 mg showed the most significant reductions in body mass index (systematic review of three trials).

    In plain wordsIn adults with obesity, the 12 mg dose of retatrutide gave the largest drops in body mass index among the doses.

    Peptide
    Retatrutide
    Outcome
    DecreaseBody mass index reduction
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    12 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The 12 mg dosage of retatrutide showed the most significant reductions in body weight, body mass index, and waist circumference.
    2 context sentences
    Summary · context
    Three articles were included in this systematic review, screening a total of 1,082 patients, with 691 randomly assigned to groups.
    Summary · context
    Retatrutide was administered to 510 participants, while 130 received a placebo.
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with obesity, retatrutide 12 mg showed the most significant reductions in waist circumference (systematic review of three trials).

    In plain wordsIn adults with obesity, the 12 mg dose of retatrutide gave the largest drops in waist circumference among the doses.

    Peptide
    Retatrutide
    Outcome
    DecreaseWaist circumference reduction
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    12 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The 12 mg dosage of retatrutide showed the most significant reductions in body weight, body mass index, and waist circumference.
    2 context sentences
    Summary · context
    Three articles were included in this systematic review, screening a total of 1,082 patients, with 691 randomly assigned to groups.
    Summary · context
    Retatrutide was administered to 510 participants, while 130 received a placebo.
  4. 04HumanSystematic reviewEfficacy outcome

    In adults with obesity, retatrutide 12 mg led to a higher percentage of patients reaching weight losses of 5, 10, 15 and 20% or more (systematic review of three trials).

    In plain wordsIn adults with obesity, more people on the 12 mg dose of retatrutide reached weight loss targets of 5% up to 20%.

    Peptide
    Retatrutide
    Outcome
    IncreaseProportion with weight loss of 5, 10, 15 and 20% or more
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    12 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    It also led to a higher percentage of patients achieving weight losses of ≥5 , 10, 15, and 20 %.
    2 context sentences
    Summary · context
    Three articles were included in this systematic review, screening a total of 1,082 patients, with 691 randomly assigned to groups.
    Summary · context
    Retatrutide was administered to 510 participants, while 130 received a placebo.
  5. 05HumanSystematic reviewSafety outcome

    In adults with obesity, gastrointestinal adverse effects were the most commonly reported adverse effects of retatrutide (systematic review of three trials).

    In plain wordsIn adults with obesity, stomach and gut side effects were the side effects most often reported with retatrutide.

    Peptide
    Retatrutide
    Outcome
    Direction not reportedGastrointestinal adverse effects
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Gastrointestinal adverse effects were the most commonly reported.
    2 context sentences
    Summary · context
    Three articles were included in this systematic review, screening a total of 1,082 patients, with 691 randomly assigned to groups.
    Summary · context
    Retatrutide was administered to 510 participants, while 130 received a placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.